The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy

Sugiyama, Keiji; Shiraishi, Kazuhiro; Motohashi, Takuya; Onoda, Shigeki; Sato, Mariko; Katō, K.; Uda, Hiroaki; Hattori, Minoru; Suenaga, Masaya; Hirashima, Noboru; Shimada, Muneaki; Kataoka, Masato; Kitagawa, Chiyoe

doi:10.1080/01635581.2022.2162090

Cited by 3 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite receiving anamorelin treatment, BW gain after 12 weeks remained at 47%, underscoring the importance of considering further treatment strategies for cancer cachexia. Sugiyama et al conducted a study on primary chemotherapy and nutritional support for unresectable advanced GC and found that nutritional support contributed to an extension in TTF, according to their multivariate analysis (Sugiyama et al 2023). Additionally, their study identi ed low BMI and an mGPS of 1 or higher as poor prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer

Matsumoto,

Cho,

Nakasya

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. Methods: We retrospectively collected real-world data from patients with colorectal and gastric cancer with cachexia who received anamorelin. Efficacy was assessed based on appetite improvement and body weight (BW) gain. Results: Forty-three patients with cancer and cachexia received anamorelin between June 2021 and October 2022 (23 with gastric cancer, 20 with colorectal cancer). The median observation time was 7.3 months, 25 patients were male, the median age was 71 years, the median body mass index was 19.7, and the ECOG PS 0/1/2 ratio was 4/33/6. Seven patients received best supportive care only, and 36 received concomitant chemotherapy with anamorelin. Thirty-four patients received prior chemotherapy with two or fewer regimens, while nine received three or more regimens. The median anamorelin treatment duration was 2.8 months, and overall survival (OS) from the first anamorelin administration was 7.3 months. Twenty-four and 21 patients experienced appetite improvement and BW gain, respectively, at 3 weeks, as did 20 and 15 at 12 weeks, respectively. In the multivariate analysis, anamorelin administration before second-line chemotherapy and colorectal cancer correlated with appetite improvement and BW gain after 3 weeks. Furthermore, anamorelin administration before second-line chemotherapy correlated with BW gain after 12 weeks in the univariate analysis, and OS significantly improved in patients with BW gain after 12 weeks. Conclusion: Early anamorelin contributes to appetite improvement and BW gain in colorectal and gastric cancer with cachexia.

show abstract

Section: Discussionmentioning

confidence: 99%

Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer

Matsumoto,

Cho,

Nakasya

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…However, despite receiving anamorelin treatment, BW gain after 12 weeks remained at 47%, underscoring the importance of considering further treatment strategies for cancer cachexia. Sugiyama et al conducted a study on primary chemotherapy and nutritional support for unresectable advanced GC and found that nutritional support contributed to an extension in TTF, according to their multivariate analysis [29]. Additionally, their study identi ed low BMI and an mGPS of 1 or higher as poor prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer: An observational study

Matsumoto,

Cho,

Nakasya

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. Methods We retrospectively collected real-world data from patients diagnosed with colorectal and gastric cancers experiencing cachexia who were treated with anamorelin. We evaluated the efficacy of treatment by measuring the improvements in appetite and body weight (BW) gain. Results Between June 2021 and October 2022, 43 cancer patients with cachexia—23 with gastric cancer and 20 with colorectal cancer—were treated with anamorelin. Median observation period was 7.3 months. The participants were 25 males with median age of 71 years and median BMI of 19.7. The ECOG PS distribution was 4, 33, 6 for grades 0, 1, and 2, respectively. Seven patients received supportive care only, while 36 received anamorelin with chemotherapy. Thirty-four had received chemotherapy previously (≤ 2 regimens) and nine had received ≥ 3 regimens. Median anamorelin treatment duration was 2.8 months; overall survival was 7.3 months. After 3 weeks, 24 experienced appetite improvement and 21 gained weight; after 12 weeks, 20 experienced appetite improvement and 15 gained weight. Multivariate analysis showed that anamorelin treatment before second-line chemotherapy and colorectal cancer correlated with appetite improvement and weight gain at 3 weeks. In the univariate analysis, anamorelin treatment before second-line chemotherapy correlated with weight gain at 12 weeks and with improved overall survival in patients with weight gain at 12 weeks. Conclusion Early anamorelin treatment contributes to appetite improvement and BW gain in colorectal and gastric cancers with cachexia.

show abstract

“…While the administration of home parenteral nutrition (PN) has shown improvements in nutritional markers like albumin, prealbumin, cholesterol, high‐density lipoprotein, and low‐density lipoprotein, it did not demonstrate a positive effect on overall survival (OS) 81 . Similarly dietary counseling and support did not significantly impact OS, but it was a prognostic factor for time to treatment failure, defined as the duration from start to discontinuation of chemotherapy 82 …”

Section: Clinical Impact Of Malnutritionmentioning

confidence: 99%

“… 81 Similarly dietary counseling and support did not significantly impact OS, but it was a prognostic factor for time to treatment failure, defined as the duration from start to discontinuation of chemotherapy. 82 …”

Section: Clinical Impact Of Malnutritionmentioning

confidence: 99%

Impact of malnutrition and nutritional support after gastrectomy in patients with gastric cancer

Kang,

Lee

2024

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Malnutrition, characterized by altered body composition and impaired function, is particularly prevalent among gastric cancer patients, affecting up to 60% of them. Malnutrition in these patients can manifest both before and after surgery, due to factors such as gastric outlet obstruction, cancer cachexia, and anatomical changes. Notably, total gastrectomy (TG) presents the most significant nutritional challenges. However, function‐preserving gastrectomy, such as pylorus‐preserving gastrectomy (PPG) and proximal gastrectomy (PG), have shown promise in improving nutritional outcomes. Effective nutritional risk screening and assessment are vital for identifying patients at risk. Nutritional support not only improves nutritional parameters but also reduces complications, enhances quality of life (QoL) and survival rates. Those unable to maintain more than 50% of the recommended intake for over 7 days are recommended for nutritional support. Common methods of nutritional support include oral nutrition supplements (ONS), enteral nutrition (EN), or parenteral nutrition (PN) depending on the patient's status. Effect of perioperative nutritional support remains controversial. Preoperative interventions including ONS and PN have shown mixed results, with selective benefits in patients with sarcopenia or hypoalbuminaemia, while impact of EN in gastric outlet obstruction patients have been positive. In contrast postoperative support appears to be consistent. Tube feeding after TG has shown improvements, and ONS have been effective in reducing weight loss and improving nutritional biomarkers. PN was also associated with benefits such as weight maintenance and QoL. This review explores the mechanisms, assessment, and clinical impact of malnutrition, emphasizing the importance of nutritional support in gastric cancer patients undergoing gastrectomy.

show abstract

The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy

Cited by 3 publications

References 40 publications

Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer

Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer

Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer: An observational study

Impact of malnutrition and nutritional support after gastrectomy in patients with gastric cancer

Contact Info

Product

Resources

About